Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio— have products in the pipeline that could ...

Paramount+ brings us a new dramatic series that promises to captivate true crime enthusiasts. Happy Face follows the story of ...

Dennis Quaid stars as the notorious Happy Face Killer, aka Keith Hunter Jesperson, in the upcoming Paramount+ drama series “Happy Face.” ...

Hearing Loss and Facial Weakness Complications of herpes zoster oticus and Ramsay Hunt syndrome might include hearing loss ... Centers for Disease Control and Prevention. Clinical features of shingles ...

PAUL HUNTER was an iconic snooker player when he was alive and his legacy has continued long after his death aged just 27. Every year at the Masters tournament the sportsman is remembered ...

Fifteen-year-old Dominic Henriquez from Prosper, Texas, is bringing hope to boys like him who live with Hunter syndrome, a rare genetic disorder that primarily affects males. Dominic’s journey ...

Nip­pon Shinyaku has paid $110 mil­lion up­front for the rights to sell two of Re­genxbio’s gene ther­a­pies for mu­copolysac­cha­ri­do­sis in the US and Asia. … ...

RegenxBio said Tuesday that Kyoto, Japan’s Nippon Shinyaku Co. Ltd. will develop and commercialize its one-time gene therapies for Hunter syndrome and Hurler syndrome, both affecting children.

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.

The partnership will focus on advancing RGX-121 as a treatment for mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, and RGX-111 for treating mucopolysaccharidosis I (MPS I), also ...

One of the treatments, for a progressive disorder known as Hunter syndrome, could secure approval in the U.S. as soon as late this year. Should that happen, Regenxbio will retain rights to any ...